Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
Tango's cancer drug worked well in early testing, showing 82% of patients responded. The stock fell anyway, which means investors wanted even better results or worry about future challenges ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.